"Muromonab-CD3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti).
| Descriptor ID |
D016853
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075.570 D12.776.124.486.485.114.619.393.570 D12.776.124.790.651.114.224.075.570 D12.776.124.790.651.114.619.393.570 D12.776.377.715.548.114.224.284.570 D12.776.377.715.548.114.619.393.570
|
| Concept/Terms |
Muromonab-CD3- Muromonab-CD3
- Muromonab CD3
- OKT3
- Monoclonal Antibody OKT3
|
Below are MeSH descriptors whose meaning is more general than "Muromonab-CD3".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Muromonab-CD3 [D12.776.124.486.485.114.224.075.570]
- Immunoglobulin Isotypes [D12.776.124.486.485.114.619]
- Immunoglobulin G [D12.776.124.486.485.114.619.393]
- Muromonab-CD3 [D12.776.124.486.485.114.619.393.570]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Muromonab-CD3 [D12.776.124.790.651.114.224.075.570]
- Immunoglobulin Isotypes [D12.776.124.790.651.114.619]
- Immunoglobulin G [D12.776.124.790.651.114.619.393]
- Muromonab-CD3 [D12.776.124.790.651.114.619.393.570]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Muromonab-CD3 [D12.776.377.715.548.114.224.284.570]
- Immunoglobulin Isotypes [D12.776.377.715.548.114.619]
- Immunoglobulin G [D12.776.377.715.548.114.619.393]
- Muromonab-CD3 [D12.776.377.715.548.114.619.393.570]
Below are MeSH descriptors whose meaning is more specific than "Muromonab-CD3".
This graph shows the total number of publications written about "Muromonab-CD3" by people in this website by year, and whether "Muromonab-CD3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Muromonab-CD3" by people in Profiles.
-
iCaspase 9 Suicide Gene System. Methods Mol Biol. 2015; 1317:87-105.
-
Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients. Clin Transplant. 2011 Nov-Dec; 25(6):E584-91.
-
Engineered T cells for pancreatic cancer treatment. HPB (Oxford). 2011 Sep; 13(9):643-50.
-
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother. 2011 Apr; 34(3):236-50.
-
2E8 binds to the high affinity I-domain in a metal ion-dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1. J Biol Chem. 2010 Oct 22; 285(43):32860-32868.
-
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood. 2008 Apr 15; 111(8):4392-402.
-
Distinct spatial and temporal distribution of ZAP70 and Lck following stimulation of interferon and T-cell receptors. J Mol Biol. 2005 Nov 11; 353(5):1001-10.
-
Pharmacologic immunosuppression. Front Biosci. 2004 Jan 01; 9:411-20.
-
The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl. 2003 Nov; 9(11):S79-89.
-
Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis. Transpl Int. 2001 Aug; 14(4):234-9.